GGrantIndex
← Leaderboards

Ulrich Wiesner

Sloan-Kettering Inst Can Research

$4,616,977
Attributed
$9,040,368
Total exposure
4
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY201224
$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$17,364,169 · 5

By mechanism

U54$10,216,937 · 2
R01$7,147,232 · 3

Top collaborators

Most similar at Sloan-Kettering Inst Can Research

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoMelanomaDesignParticleIn VitroPropertyTumorMolecularMalignant NeoplasmsNanoparticleTranslationsSilicon DioxideBaseLeadGenerationsPositron-Emission TomographyClinical TrialsChemistryMetastatic MelanomaOpticsStagingBiologicalDetectionSurface

Grant awards (25)

Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer$494,251
R01 · FY2024 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer$550,839
R01 · FY2023 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer$64,250
R01 · FY2023 · CA
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles$1
R01 · FY2023 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer$635,854
R01 · FY2022 · CA
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles$538,399
R01 · FY2022 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer$637,054
R01 · FY2021 · CA
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles$435,128
R01 · FY2021 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer$658,454
R01 · FY2020 · CA
Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles$396,582
R01 · FY2020 · CA
MSKCC -Cornell Center for Translation of Cancer Nanomedicines.$1,664,540
U54 · FY2019 · CA
Highly-Integrated Ultrasmall and Bright Fluorescent Silica Particle Architectures$379,708
U54 · FY2019 · CA · contact PI
MSKCC -Cornell Center for Translation of Cancer Nanomedicines.$1,595,317
U54 · FY2018 · CA
Highly-Integrated Ultrasmall and Bright Fluorescent Silica Particle Architectures$380,695
U54 · FY2018 · CA · contact PI
MSKCC -Cornell Center for Translation of Cancer Nanomedicines.$1,604,099
U54 · FY2017 · CA
Highly-Integrated Ultrasmall and Bright Fluorescent Silica Particle Architectures$380,767
U54 · FY2017 · CA · contact PI
MSKCC -Cornell Center for Translation of Cancer Nanomedicines.$1,791,702
U54 · FY2016 · CA
Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Ra$493,088
R01 · FY2016 · CA
Highly-Integrated Ultrasmall and Bright Fluorescent Silica Particle Architectures$379,145
U54 · FY2016 · CA · contact PI
MSKCC -Cornell Center for Translation of Cancer Nanomedicines.$1,668,143
U54 · FY2015 · CA
Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Ra$504,474
R01 · FY2015 · CA
Highly-Integrated Ultrasmall and Bright Fluorescent Silica Particle Architectures$372,821
U54 · FY2015 · CA · contact PI
Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Ra$549,873
R01 · FY2014 · CA
Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Ra$501,146
R01 · FY2013 · CA
Renally Excreted Multimodal Core-Shell Silica Nanoparticles as Tumor-Selective Ra$687,839
R01 · FY2012 · CA